1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,300 | 11,400 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 1 | Benzinga.com | ||
| Di | Piper Sandler initiates Agomab stock with Overweight rating | 3 | Investing.com | ||
| Di | XFRA NEW INSTRUMENTS AVAILABLE ON 25.08.2026 | 401 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.08.2026
Aktien
1 US00860C1027 AgomAb Therapeutics... ► Artikel lesen | |
| 10.08. | Agomab proposes two board members for shareholder vote | 1 | Investing.com | ||
| 10.08. | Agomab proposes two new board members, sets shareholder vote | 1 | Investing.com | ||
| 10.08. | AgomAb Therapeutics NV: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | 148 | GlobeNewswire (Europe) | Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced... ► Artikel lesen | |
| 23.07. | B.Riley initiates Agomab Therapeutics stock with buy rating | 1 | Investing.com | ||
| 23.06. | Agomab gibt Design für Phase-2b-Studie zu Morbus-Crohn-Medikament bekannt | 4 | Investing.com Deutsch | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.06. | Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib | 1 | Benzinga.com | ||
| 23.06. | Agomab announces Phase 2b study design for Crohn's disease drug | 1 | Investing.com | ||
| 23.06. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | AgomAb Therapeutics NV: Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease | 520 | GlobeNewswire (Europe) | -- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation... ► Artikel lesen | |
| 22.06. | H.C. Wainwright initiates Agomab stock coverage with buy rating | 1 | Investing.com | ||
| 27.05. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | AgomAb Therapeutics NV: Agomab Announces Results of Annual General Meeting | 195 | GlobeNewswire (Europe) | Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual... ► Artikel lesen | |
| 24.04. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | AgomAb Therapeutics NV: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook | 328 | GlobeNewswire (Europe) | -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --... ► Artikel lesen | |
| 23.04. | Agomab Therapeutics NV - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Agomab receives U.S. patent for lung fibrosis drug candidate | 3 | Investing.com | ||
| 26.03. | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 192 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,228 | +2,24 % | BioNxt erreicht wichtigen Meilenstein im klinischen Cladribin-Programm für MS mit Abschluss des IMPD vor Beginn der klinischen Studien am Menschen | VANCOUVER, BC / ACCESS Newswire /
26. August 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,460 | +2,06 % | Arbutus launches $230 million share buyback tender offer | ||
| ATAIBECKLEY | 6,300 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| ALDEYRA | 1,290 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ABCELLERA BIOLOGICS | 9,790 | 0,00 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 21,900 | +0,69 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| AC IMMUNE | 2,300 | 0,00 % | AC Immune: H.C. Wainwright bestätigt Kaufempfehlung nach Phase-1-Daten | ||
| BIOXCEL THERAPEUTICS | 0,156 | +6,51 % | BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals | BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as "stalking horse" bidder in a court-supervised... ► Artikel lesen | |
| AGENUS | 6,850 | +3,01 % | Agenus reports survival data for colorectal cancer treatment | ||
| ARCTURUS THERAPEUTICS | 15,190 | 0,00 % | Arcturus, Moderna fall after BioNTech's cancer vaccine setback | ||
| ARDELYX | 3,325 | +0,91 % | Ardelyx, Inc.: Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx | WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,901 | +12,57 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update | Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer's Disease Clinical Study... ► Artikel lesen | |
| ACTINIUM | 0,849 | -1,96 % | Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update | NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted... ► Artikel lesen |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,88 % bei einem Aktienkurs von 11,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.